Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
20 February 2023 |
Main ID: |
NCT04121780 |
Date of registration:
|
25/09/2019 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Growth Hormone Replacement Therapy for Retried Professional Football Players
|
Scientific title:
|
Interventional Study of Growth Hormone Replacement Therapy in Retired Professional Football Players With Growth Hormone Deficiency |
Date of first enrolment:
|
October 8, 2019 |
Target sample size:
|
42 |
Recruitment status: |
Recruiting |
URL:
|
https://clinicaltrials.gov/show/NCT04121780 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
|
Phase:
|
Phase 2
|
|
Countries of recruitment
|
United States
| | | | | | | |
Contacts
|
Name:
|
Randall R Benson, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Vice President and Medical Director |
|
Name:
|
Vijay M Baragi, Ph.D. |
Address:
|
|
Telephone:
|
313-228-0930. |
Email:
|
vijay@neurologicstudies.com |
Affiliation:
|
|
|
Name:
|
Vijay Baragi, Ph.D. |
Address:
|
|
Telephone:
|
313-228-0930 |
Email:
|
vijay@neurologicstudies.com |
Affiliation:
|
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- The subject is willing to provide a signed and dated informed consent indicating that
he understands the purpose and procedures required for the study and is willing to
participate in the study.
- Former NFL player
- At least one year since retirement from football
- Less than 76 years of age
- Diagnosis of GHD on clinical grounds by a neurologist and an endocrinologist GHD
Exclusion Criteria:
- History of pre-existing brain disease other than concussion or TBI
- History of a premorbid disabling condition that interferes with outcome assessments
- Contraindication to GH therapy
- Type I and II Diabetes mellitus
- Active malignant disease
- Acute critical illness, heart failure, or acute respiratory failure
- Subjects who are deficient in cortisol, testosterone or thyroid at screening will be
excluded until hormone abnormalities have been corrected.
Age minimum:
18 Years
Age maximum:
76 Years
Gender:
Male
|
Health Condition(s) or Problem(s) studied
|
TBI (Traumatic Brain Injury)
|
Concussion, Brain
|
Anterior Pituitary Hyposecretion Syndrome
|
Hypopituitarism
|
Growth Hormone Deficiency
|
Sport Injury
|
Intervention(s)
|
Other: Placebo
|
Biological: Growth Hormone
|
Primary Outcome(s)
|
Cognitive functions- ANAM ( Automated Psychological Assessment Metrics)
[Time Frame: From baseline to 1-year post-treatment]
|
Cognitive functions- Verbal learning and memory
[Time Frame: From baseline to 1-year post-treatment]
|
Cognitive functions- Working Memory
[Time Frame: From baseline to 1-year post-treatment]
|
Cognitive functions- Processing Speed
[Time Frame: From baseline to 1-year post-treatment]
|
Cognitive functions- Executive Function.
[Time Frame: From baseline to 1-year post-treatment]
|
Secondary Outcome(s)
|
Change in Physical function- Peak O2 consumption (Vo2 max)
[Time Frame: One year (from baseline to 1-year post-treatment)]
|
Change in QEEG Markers- power spectra
[Time Frame: One year (from baseline to 1-year post-treatment)]
|
Change in Physical function- Isokinetic knee extension peak torque
[Time Frame: One year (from baseline to 1-year post-treatment)]
|
Adverse events
[Time Frame: One year (from baseline to 1-year post-treatment)]
|
MRI
[Time Frame: One year (from baseline to 1-year post-treatment)]
|
Change in QEEG Markers- Connectivity Measures
[Time Frame: One year (from baseline to 1-year post-treatment)]
|
Quality of Life Assessment of Growth Hormone Deficiency in Adults
[Time Frame: One year (from baseline to 1-year post-treatment)]
|
Change in Physical function- Maximum grip strength
[Time Frame: One year (from baseline to 1-year post-treatment)]
|
Change in Physical function-DEXA measure
[Time Frame: One year (from baseline to 1-year post-treatment)]
|
Secondary ID(s)
|
UTN: U1111-1201-5972
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|